Article

Dual targeting of PDPK1 and BRAF V600E is synthetically lethal

2026-03-18

Abstract excerpt

<h4>ABSTRACT</h4> PDPK1 functions downstream of PI3K and is essential for activating AKT and other AGC kinases. Although PDPK1 has a central role in the PI3K/AKT/mTOR signaling pathway, there has been limited evaluation of it as a target for cancer therapy. Anaplastic thyroid cancer (ATC) has one of the highest mortality rates of all human malignancies. Although combined BRAF and MEK inhibition in BRAF V600E muta...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 037939ce-fcf5-586e-bbd8-ab8d400a9f1a
DOI: 10.64898/2026.03.15.711663

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dual targeting of PDPK1 and BRAF V600E is synthetically lethalDOI 10.64898/2026.03.15.711663Read

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations.Semantic proximity Read

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsSemantic proximity Read

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.Semantic proximity Read

NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma.Semantic proximity Read

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.Semantic proximity Read

Genetic alterations in anaplastic thyroid carcinoma and targeted therapies (Review)Semantic proximity Read

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapiesSemantic proximity Read

Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment StrategySemantic proximity Read

c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.Semantic proximity Read

Clinical Development of BRAF plus MEK Inhibitor Combinations.Semantic proximity Read

A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).Semantic proximity Read